Contact us on 0115 787 0206 or at info@vformation.biz

Significant growth for Boyds

Significant growth for Boyds
May 7, 2019 Lucy Wharton

Congratulations to V Formation client, Boyds, which has recently announced the opening of two new offices, four key appointments and the launch of a Clinical and Medical affairs group, as part of its 2019 growth strategy.

New facilities

A leading consultancy business supporting the development of pharmaceutical and biotech products for patient benefit, Boyds has its headquarters in Crewe, premises in Cambridge, and has expanded into Alderley Park and Dublin City University’s Innovation Centre, Invent.

The move to Alderley Park will enable Boyds, who won the Queen’s Award for Enterprise last year, to forge stronger links with other life science businesses in the North West region, which is a hotbed for medtech and biotech businesses.

Professor Alan Boyd

Professor Alan Boyd

The Dublin office will provide Boyds with the foothold it needs in Europe to ensure clients can continue to benefit from access to the European Medicines Agency (EMA) following Brexit, as Boyds’ Founder and CEO, Professor Alan Boyd explains:

“The opening of our Dublin office is especially important to the work we do in supporting the development of medicines for patient benefit.

“We work with clients across the globe who come to us for our regulatory expertise, and who wish to benefit from the easy access to the EMA that allows them to get development advice and gain market authorisation for their drugs and medical devices. We need to ensure we are positioned to continue this vital work with the EMA.

“The Dublin office is a significant step in Boyds’ ongoing expansion strategy, and Brexit aside, this is an important move for us as a business so we can continue to create further opportunities in Ireland and beyond.”

Key appointments

Boyds has appointed Siobhan Gaynor to head up the office in Dublin as Consultant of Business Development and Affairs. Siobhan has over 28 years’ experience in a wide variety of research, business development and executive roles in clinical and translational health research across major pharmaceutical companies, biotechnology start-ups and academia, including Spark Therapeutics, GlaxoSmithKline, Clinical Research Development Ireland and Cancer Trials Ireland.

Dr Sabine Rühle also joins Boyds as Senior Associate of Regulatory Affairs, and will be based at Boyds’ Cambridge offices. A member of the Organisation of Professionals in Regulatory Affairs (MTOPRA), Sabine joins from Pharmaceutical Product Development, where she was Senior Regulatory Affairs Specialist and coordinated global CTA submissions for a variety of products and therapeutic indications.

Claire Scruton joined this month as Senior Manager, CMC Regulatory Affairs and will also be based in the Cambridge office. Claire joins from Mundipharma and brings over 20 years’ experience in the pharmaceutical industry, including an extensive background in biological and inhalation product development.

Clinical and Medical Affairs Group

Professor Alan Boyd has also formally established a Clinical and Medical Affairs Group to provide pharmaceutical medicine and medical monitoring support to its clients and their programmes. Dr Lalitha Mahadavan has been appointed as Director of Clinical and Medical AffairsBoyds and will head up the Cambridge-based Group, which will provide a multi-speciality consulting service to Boyds’ client base.

Experienced in leading global business critical projects, and regulatory submissions for biopharmaceutical companies including Johnson & Johnson, Biogen and the NHS, Lalitha is a Consultant in Pharmaceutical Medicine (GMC Registered) and a Fellow of the Faculty of Pharmaceutical Medicine, as well as a member of its Board of Trustees and a Faculty Revalidation Appraiser.

V Formation’s Sue Carr is Boyds’ outsourced marketing consultant and has worked with the business for more than four years providing strategic marketing communications and PR support and advice.